Synonyms: ALD-518 | ALD518 | BMS-945429
Compound class:
Antibody
Comment: Clazakizumab is an investigational, aglycosylated, humanized (from a rabbit parental antibody) monoclonal antibody targeting interleukin-6, with anti-inflammatory potential [2].
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. BLAST peptide sequence analysis reveals identical matches with peptides claimed in patent US8062864 [3]. Results presented in the patent show that the preferred antibodies block interaction of IL-6 with the IL-6 receptor, but no precise binding affinity data is provided. |
Classification | |
Compound class | Antibody |
International Nonproprietary Names | |
INN number | INN |
9599 | clazakizumab |
Synonyms |
ALD-518 | ALD518 | BMS-945429 |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 414 |
Other databases | |
GtoPdb PubChem SID | 315661274 |
Search PubMed clinical trials | clazakizumab |
Search PubMed titles | clazakizumab |
Search PubMed titles/abstracts | clazakizumab |
Wikipedia | Clazakizumab |